^Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A (2000), “Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?”, Acta Haematol.104 (1): 10–5, PMID (11111115)
^Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL (November 2001), “Association between myeloperoxidase levels and risk of coronary artery disease”, JAMA286 (17): 2136–42, doi:10.1001/jama.286.17.2136, PMID (11694155)
^Lau D, Baldus S (July 2006), “Myeloperoxidase and its contributory role in inflammatory vascular disease”, Pharmacol. Ther.111 (1): 16–26, doi:10.1016/j.pharmthera.2005.06.023, PMID (16476484)
^Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL (October 2003), “Prognostic value of myeloperoxidase in patients with chest pain”, N. Engl. J. Med.349 (17): 1595–604, doi:10.1056/NEJMoa035003, PMID (14573731)
^Heslop CL, Frohlich JJ, Hill JS (March 2010), “Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography”, J. Am. Coll. Cardiol.55 (11): 1102–9, doi:10.1016/j.jacc.2009.11.050, PMID (20223364)
^Edward G W, Michael JB (April 2001), “Flow cytometry in the diagnosis of acute leukemia”, Seminars in Hematology38 (2): 124-138, doi:10.1016/S0037-1963(01)90046-0
^Leong A S-Y, Cooper K, Leong, FJ W-M (2003), Manual of Diagnostic Antibodies for Immunohistology, London: Greenwich Medical Media, pp. 325-326, ISBN (1-84110-100-1)
^Kagan VE, Konduru NV, Feng W, Allen BL, Conroy J, Volkov Y, Vlasova II, Belikova NA, Yanamala N, Kapralov A, Tyurina YY, Shi J, Kisin ER, Murray AR, Franks J, Stolz D, Gou P, Klein-Seetharaman J, Fadeel B, Star A, Shvedova AA (April 2010), “Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation”, Nat Nanotechnol5 (5): 354–9, doi:10.1038/nnano.2010.44, PMID (20364135), 非専門家向けの内容要旨 – popsci.com